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ExtEndEd rEport
Early and sustained efficacy with apremilast 
monotherapy in biological-naïve patients with 
psoriatic arthritis: a phase IIIB, randomised controlled 
trial (ACTIVE)
peter nash,1 Kamal ohson,2 Jessica Walsh,3 nikolay delev,4 dianne nguyen,4 
Lichen teng,4 Juan J Gómez-reino,5 Jacob A Aelion,6 on behalf of the ACtIVE 
investigators
AbstrACt
Objective Evaluate apremilast efficacy across various 
psoriatic arthritis (psA) manifestations beginning at week 
2 in biological-naïve patients with psA.
Methods patients were randomised (1:1) to apremilast 
30 mg twice daily or placebo. At week 16, patients 
whose swollen and tender joint counts had not improved 
by ≥10% were eligible for early escape. At week 24, all 
patients received apremilast through week 52.
results Among 219 randomised patients (apremilast: 
n=110; placebo: n=109), a significantly greater American 
College of rheumatology 20 response at week 16 
(primary outcome) was observed with apremilast versus 
placebo (38.2% (42/110) vs 20.2% (22/109); p=0.004); 
response rates at week 2 (first assessment) were 16.4% 
(18/110) versus 6.4% (7/109) (p=0.025). Improvements 
in other efficacy outcomes, including 28-joint count 
disease Activity Score (dAS-28) using C reactive 
protein (Crp), swollen joint count, Health Assessment 
Questionnaire-disability Index (HAQ-dI), enthesitis and 
morning stiffness severity, were observed with apremilast 
at week 2. At week 16, apremilast significantly reduced 
psA disease activity versus placebo, with changes in 
dAS-28 (Crp) (p<0.0001), HAQ-dI (p=0.023) and 
Gladman Enthesitis Index (p=0.001). Improvements were 
maintained with continued treatment through week 52. 
over 52 weeks, apremilast’s safety profile was consistent 
with prior phase 3 studies in psoriasis and psA. during 
weeks 0–24, the incidence of protocol-defined diarrhoea 
was 11.0% (apremilast) and 8.3% (placebo); serious 
adverse event rates were 2.8% (apremilast) and 4.6% 
(placebo).
Conclusions In biological-naïve patients with psA, 
onset of effect with apremilast was observed at week 2 
and continued through week 52. the safety profile was 
consistent with previous reports.
trial registration number nCt01925768; results.
IntrOduCtIOn
Psoriatic arthritis (PsA) is heterogeneous, with 
patients exhibiting varied clinical symptoms, 
severity and disease course. Treatment goals include 
controlling disease activity, optimising functional 
status and minimising side effects to therapy.1 
Biologicals are commonly used after or in conjunc-
tion with conventional synthetic disease-modifying 
antirheumatic drugs (csDMARDs), but safety moni-
toring and risks may limit their long-term use.2 3 
The efficacy and safety of apremilast, an oral 
phosphodiesterase 4 inhibitor, were demonstrated 
in patients with active PsA in four phase III, 
placebo-controlled studies as part of the Psoriatic 
Arthritis Long-term Assessment of Clinical Efficacy 
(PALACE) clinical trial programme.4–7 The PALACE 
1, 2 and 3 studies evaluated apremilast in patients 
with prior exposure to csDMARDs and/or biolog-
icals and allowed concomitant csDMARD use.4–6 
PALACE 4 evaluated apremilast monotherapy in 
csDMARD-naïve and biological-naïve popula-
tions.7 Data demonstrating apremilast’s efficacy 
across disease manifestations have been reported 
at week 164–6 8 and up to 4 years of treatment.9 
However, time to onset of therapeutic effect has not 
been reported before week 16.
Assessing Apremilast Monotherapy in a Clinical 
Trial of BIologic-NaïVE Patients With Psoriatic 
Arthritis (ACTIVE) aimed to evaluate apremilast 
monotherapy in biological-naïve PsA patients who 
may have had one prior csDMARD. ACTIVE also 
aimed to determine the onset of apremilast effi-
cacy, with assessments beginning at week 2, and to 
examine additional outcome measures, including 
morning stiffness and enthesitis using the Gladman 
Enthesitis Index (GEI).10 Diarrhoea adverse events 
(AEs) were further characterised using a protocol 
definition.
This report describes the early onset and overall 




Enrolled adults (≥18 years of age) had a docu-
mented diagnosis of active PsA for ≥3 months and 
met Classification Criteria for Psoriatic Arthritis.11 
At screening, patients were required to have at 
least three swollen and three tender joints, C reac-
tive protein (CRP) of ≥0.2 mg/dL and be biolog-
ical DMARD-naïve. No csDMARD washout 
before the study was required (except 4 weeks 
for cyclosporine and 12 weeks for leflunomide); 
however, patients had to discontinue their current 
csDMARD ≥1 day before baseline assessments. 
Patients were excluded if they had prior treatment 
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with more than one csDMARD; used prohibited systemic ther-
apies, including cyclosporine or other calcineurin inhibitors, 
within 4 weeks of randomisation, corticosteroids >10 mg daily 
(prednisone or equivalent), oral agents such as retinoids, myco-
phenolate, thioguanine, hydroxyurea, sirolimus and tacrolimus; 
and inflammatory joint disease other than PsA. Also excluded 
were patients with active or incompletely treated tuberculosis, 
significant infection within 4 weeks of screening and current or 
history of malignancy (except for treated basal cell or squamous 
cell skin carcinoma or early forms of cervical carcinoma with no 
recurrence within 5 years).
All patients provided written informed consent before any 
study procedures were initiated.
study design
This phase IIIB, multicentre, randomised, double-blind, place-
bo-controlled, parallel-group study evaluated the efficacy and 
safety of apremilast monotherapy in patients with active PsA.
Patients were randomised (1:1) to apremilast 30 mg twice 
daily or placebo for 24 weeks, stratified by previous csDMARD 
and baseline prednisone (or equivalent) use. Patients who did 
not improve by ≥10% in swollen joint count (SJC) and tender 
joint count (TJC) at week 16 were eligible for early escape at 
the investigator’s discretion. Early escape patients initially 
randomised to placebo were switched to apremilast in blinded 
fashion, with dose titration during the first week of treat-
ment; patients initially randomised to apremilast remained on 
apremilast. At week 24, all remaining patients receiving placebo 
switched to apremilast for the active treatment phase through 
week 52, when all patients were eligible to continue apremilast 
treatment in an open-label extension phase through week 104.
Concomitant medications
Patients could receive concurrent treatment with stable doses 
of oral corticosteroids (prednisone ≤10 mg/day or equivalent), 
non-steroidal anti-inflammatory drugs or opioid analgesics. 
Changes in corticosteroid doses and/or discontinuations were 
not allowed from day 0 to week 24 except for safety reasons or 
lack of availability. After week 24, the corticosteroid dose could 
be adjusted as clinically required. Patients could use low-po-
tency topical corticosteroids for face, axillae and groin psoriatic 
lesions.
Outcomes
The primary outcome was 20% improvement in modified 
American College of Rheumatology response criteria (ACR20) 
at week 16. Other efficacy outcomes included 28-joint count 
Disease Activity Score (DAS-28) using CRP, SJC, TJC, six-point 
GEI score (0=no enthesitis, 6=all six sites active (ie, bilateral 
tibial tuberosity, plantar fascia and Achilles tendon insertion)) for 
patients with enthesitis at baseline, morning stiffness duration 
and severity, ACR50 and ACR70 and physical function assess-
ments, including the Health Assessment Questionnaire-Dis-
ability Index (HAQ-DI), 36-item Short-Form Health Survey 
version 2 (SF-36v2) Physical Functioning (PF) domain and phys-
ical component summary (PCS) scores. Safety and tolerability 
evaluations included collection of AEs, vital signs, laboratory 
evaluations, physical examinations, electrocardiograms, chest 
X-rays and further characterisation of diarrhoea AEs using a 
protocol definition (two or more watery or liquid stools/day).
Efficacy outcomes were assessed starting at week 2 and at 
scheduled visits through week 52; SF-36v2 assessments started 
at week 4.
statistical analysis
Efficacy analyses were based on the full analysis set, which 
included all randomised patients. The safety population included 
all randomised patients who received at least one dose of study 
medication. Sample size estimation was based on results from 
earlier phase III studies. A two-group χ2 (continuity-corrected) 
test with a two-sided 0.05 significance level would have ≈90% 
power to detect a true 20% difference (35% vs 15%) between 
apremilast and placebo for the proportion of patients achieving 
ACR20 response at week 16, when the sample size in each group 
was 107.
Baseline patient demographics and disease characteristics were 
compared descriptively between the treatment groups.
For the placebo-controlled period, two-sided tests for efficacy 
outcomes were performed sequentially according to a prespec-
ified hierarchical order to control the overall type I error rate 
(online supplementary table 1). P values <0.05 were considered 
statistically significant; if the P value did not reach the threshold 
of 0.05 during the hierarchical testing, the nominal P value was 
reported onwards. Therefore, P values <0.05 should be inter-
preted with caution for the secondary outcomes if a testing in 
a higher order of the hierarchy did not reach the threshold of 
0.05.
Dichotomous variables such as ACR20 response were anal-
ysed using the generalised Cochran-Mantel-Haenszel test,12 
controlling for baseline prednisone (or equivalent) use (yes/no) 
and previous csDMARD use (yes/no). Patients escaping at week 
16 were primarily treated as non-responders at the subsequent 
time points during the placebo-controlled period. Missing data 
were handled using non-responder imputation. Mixed-effect 
model for repeated measures was generally used for analyses of 
continuous variables such as HAQ-DI, where change or per cent 
change from baseline was the dependent variable and treatment 
group, time (ie, study week), treatment-by-time interaction, 
baseline prednisone (or equivalent) use (yes or no) and previous 
DMARD use (yes or no) were factors and baseline value was 
a covariate. Time was treated as a categorical variable in the 
mixed-effect model for repeated measures. Data obtained after 
early escape were excluded from the model.
Week 52 efficacy data descriptions were as-observed analyses 
when no placebo data were available for comparison.
Safety analyses were conducted for the placebo-controlled 
phase (weeks 0–24) and overall apremilast-exposure period, 
which includes all available safety data among patients who 
received at least one dose of apremilast at any time up to the 
data cut-off, at which time all patients remaining in the study 




A total of 219 patients were randomised (apremilast: n=110; 
placebo: n=109), and 84.5% completed week 24 (online supple-
mentary figure 1). Of the 180 patients entering the long-term 
active treatment phase, 88.9% completed week 52. Treatment 
groups were comparable for baseline patient demographics and 
disease characteristics (table 1).
efficacy
Primary outcome: ACR20 response
The ACR20 response rate at week 16 was significantly greater 
in patients receiving apremilast versus placebo (38.2% (42/110) 
vs 20.2% (22/109); P=0.004) (table 2), with response observed 
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at week 2 (16.4% (18/110) vs 6.4% (7/109)); P=0.025). At 
week 24, greater improvements in ACR20 response rate were 
observed with apremilast versus placebo (43.6% (48/110) vs 
24.8% (27/109); P=0.004).
Evidence of treatment effect in various additional PsA mani-
festations was observed with apremilast at week 2 (first evalua-
tion after baseline), as assessed by DAS-28 (CRP), HAQ-DI, GEI 
and morning stiffness severity (table 2).
Disease activity, joint count, enthesitis and morning stiffness 
outcomes
Efficacy was seen across a number of secondary measures 
assessing disease activity, joint inflammation, enthesitis and 
morning stiffness (table 2). At week 16, apremilast-treated 
patients demonstrated a significant reduction from baseline in 
DAS-28 (CRP) score versus placebo (P<0.0001) (table 2). Reduc-
tions continued through week 24 (−1.26 vs −0.76; P=0.005).
Significant improvement was demonstrated by mean per cent 
change in SJC with apremilast versus placebo at week 16 
(P=0.0001) (table 2), with continued improvements detected 
at week 24 (−59.1% vs −29.0%; P=0.002). Mean per cent 
changes in TJC were significant with apremilast versus placebo at 
week 16 (P=0.002) (table 2) and week 24 (−49.6% vs −25.3%; 
P=0.009).
Among patients with enthesopathy at baseline (apremilast: 
n=56; placebo: n=51), significant improvements in enthesitis 
counts were observed at week 16 (P=0.001) with apremi-
last versus placebo. Improvements were observed at week 2 
(P=0.035) and continued to week 24 (−1.5 vs −0.5; P=0.003). 
Numerically greater proportions of apremilast patients achieved 
a GEI score of 0 through week 24 (44.6% (25/56) vs 33.3% 
(17/51)).
Improvements in morning stiffness duration were observed 
with apremilast versus placebo at week 16 (P=0.005) (table 2) 
and week 24 (median per cent change: −33.3% vs 0.0%; 
P=0.001). More apremilast-treated patients showed improve-
ment in morning stiffness severity at week 16 (P=0.015) (table 2) 
continuing to week 24 (40.0% vs 20.2%; P=0.002).
Functional ability
Apremilast-treated patients experienced improvements in phys-
ical disability, as assessed by various outcomes for physical 
function. Clinically meaningful and significant improvements 
were observed in physical function, as indicated by decreases 
in HAQ-DI score at week 16 with apremilast versus placebo 
(−0.21 vs −0.06; P=0.023). Decreases were observed begin-
ning at week 2 (P=0.040) (table 2). The improvements seen with 
apremilast continued through week 24, with a mean reduction 
of −0.27; however, the mean change did not reach statistical 
significance versus placebo due to an unexpected shift in mean 
improvement in the placebo group between weeks 16 and 24 
(−0.27 vs −0.17; P=0.168).
Notably, mean changes in HAQ-DI score with apremilast 
met or exceeded the minimal clinically important difference 
(MCID) of −0.13 (prespecified analysis)13 at weeks 2, 16 and 
24. The proportion of patients achieving an MCID ≥0.35 
(post hoc analysis)14 was numerically higher with apremilast 
versus placebo at week 16 (table 2) and significantly higher 
with apremilast versus placebo at week 24 (40.9% vs 24.8%, 
P=0.014).
Significant improvement in physical function was demon-
strated by improvements from baseline in SF-36v2 PF score 
with apremilast versus placebo at week 16 (P=0.004) (table 2). 
Continued SF-36v2 PF improvement was observed at week 
24 with apremilast versus placebo (3.94 vs 1.26; P=0.017), 
with least-squares mean improvement exceeding the MCID of 
2.5.15 Similarly, significant improvements in the SF-36v2 PCS 
score were observed with apremilast versus placebo at week 16 
(P=0.0001) (table 2) and at week 24 (5.00 vs 1.60; P=0.004), 
and the least-squares mean improvement at each time point with 
apremilast exceeded the MCID of 2.5.15
Subset analysis
In a subset of patients (69% of overall population) who had 
one prior csDMARD, significant ACR20 response rates were 
observed with apremilast versus placebo (39.2% (29/74) vs 
20.5% (16/78); P=0.013) at week 16. These rates were similar 
to those observed in the overall population. Improvements in 
joint and enthesitis outcomes in the subset were also similar to 
those observed in the overall population. In the subset, the week 
16 mean per cent change with apremilast versus placebo was 
−40.7% versus 3.1% (P=0.003) for SJC and −26.8% versus 
5.4% (P=0.014) for TJC; mean change in GEI score was −1.51 
versus −0.18 (P=0.001) (online supplementary table 2). Similar 
results were observed in the subset (58% of overall population) 
with prior methotrexate use.
table 1 Baseline patient characteristics (full analysis set)
Placebo n=109
Apremilast
30 mg twice daily 
n=110
Age, mean (SD), years 48.0 (13.8) 50.7 (12.2)
Female, n (%) 65 (59.6) 58 (52.7)
White, n (%) 105 (96.3) 109 (99.1)
Region, n (%)
  North America 42 (38.5) 42 (38.2)
  Europe 38 (34.9) 47 (42.7)
  Rest of world 29 (26.6) 21 (19.1)
Weight, mean (SD), kg 90.1 (21.1) 92.6 (24.0)
Body mass index, mean (SD), kg/m2 31.8 (7.8) 32.0 (7.9)
PsA duration, mean (SD), years 3.6 (5.5) 4.0 (4.5)
SJC (0–76), mean (SD) 10.0 (5.9) 9.0 (4.9)
TJC (0–78), mean (SD) 18.4 (14.2) 17.2 (12.7)
High-sensitivity CRP, mg/dL, mean (SD) 1.25 (1.6) 1.44 (1.6)
Erythrocyte sedimentation rate, mm/h 30.3 (17.5) 33.1 (19.0)
Enthesitis*, n (%) 51 (46.8) 56 (50.9)
GEI score (0–6)†, mean (SD) 2.4 (1.6) 2.3 (1.3)
HAQ-DI sore (0–3), mean (SD) 1.20 (0.59) 1.25 (0.61)
Use of PsA-related medications
  Prior use of csDMARDs, n (%) 78 (71.6) 74 (67.3)
  Prior use of methotrexate, n (%) 66 (60.6) 61 (55.5)
  Baseline corticosteroid use‡ (mean dose, 
4.4 mg/day), n (%)
14 (12.8) 13 (11.8)
  Baseline non-steroidal anti-inflammatory 
drug use, n (%)
74 (67.9) 76 (69.1)
Note: the n reflects the number of patients who were randomised; actual number of 
patients available for each parameter may vary. 
*Pre-existing enthesopathy is defined as having a baseline GEI score greater than 0.
†Provided for patients with pre-existing enthesopathy.
‡All converted to oral prednisone dose.
CRP, C  reactive protein; csDMARDs, conventional synthetic disease-modifying 
antirheumatic drugs; GEI, Gladman Enthesitis Index; HAQ-DI, Health Assessment 
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Long-term durability
Clinical improvements across outcomes, including swollen and 
tender joints, enthesitis, morning stiffness and functional ability, 
were sustained through week 52 (table 2; figures 1–3; online 
supplementary figure 2); for individuals who received apremilast 
from baseline, mean per cent change in SJC was −77.5%, with 
55.0% (44/80) achieving SJC ≤1, and mean per cent change in 
TJC was −70.4%, with 42.5% (34/80) achieving TJC≤1.
safety
During the placebo-controlled phase (weeks 0–24), mean 
total exposure duration was 20.03 weeks (41.8 patient-years) 
for placebo patients and 20.93 weeks (43.7 patient-years) for 
apremilast patients. During the apremilast-exposure period, 
mean total duration of apremilast exposure was 52.1 weeks 
(205.6 patient-years).
Overall AE incidence through week 24 was generally similar 
between the apremilast and placebo groups (table 3). The most 
commonly reported AEs (≥5% of either treatment group) during 
the placebo-controlled phase were diarrhoea, nasopharyngitis, 
nausea, headache, hypertension and upper respiratory tract 
infection (table 3). During weeks 0–24, a total of 15 patients 
(apremilast: n=10; placebo: n=5) discontinued because of AEs. 
The nature, incidence and severity of AEs were comparable with 
longer apremilast exposure. Six patients (five randomised to 
placebo at baseline; one randomised to apremilast at baseline) 
discontinued after week 24 because of AEs (online supplemen-
tary figure 1).
Serious AEs were low for both groups (apremilast: 2.8%; 
placebo: 4.6%) during the placebo-controlled phase; none were 
considered drug related. No serious opportunistic infections, 
including new or reactivated tuberculosis, were reported during 
the study. One death occurring after week 52 was due to athero-
sclerotic cardiovascular disease in a patient with a pre-existing 
history of hypertension and alcoholic cardiomyopathy (discov-
ered at autopsy).
Diarrhoea was the most frequently reported AE during the 
placebo-controlled phase (apremilast: 14.7%; placebo: 11.0%); 
all cases were mild to moderate in severity. A protocol definition 
of diarrhoea was applied to further characterise the diarrhoea 
events. Using the criteria of two or more watery/liquid stools/
day, 21 patients had diarrhoea (apremilast: n=12 (11.0%); 
placebo: n=9 (8.3%)) during the placebo-controlled phase. 
Four of these diarrhoea events led to study discontinuation in 
apremilast-treated patients. Three (apremilast: n=1; placebo: 
n=2) of the 21 patients took antidiarrhoeal medications. From 
week 24 to week 52, 10 new patients experienced protocol-de-
fined diarrhoea AEs. Onset of diarrhoea (including protocol-de-
fined diarrhoea AEs) was most frequently observed during the 
first 4 weeks of dosing. No evidence of increased gastrointes-
tinal events was observed during the longer apremilast-exposure 
period versus the placebo-controlled phase.
No cases of suicidal ideation or behaviour occurred during the 
placebo-controlled phase or apremilast-exposure period. During 
the placebo-controlled phase, two apremilast patients experi-
enced an AE of depression; one had a history of depression and 
the other had dysthymia. Two additional AEs of depression were 
reported in the apremilast-exposure period; one patient had a 
history of depression. All four AEs of depression were not serious.
Throughout the study, markedly abnormal clinical laboratory 
values were infrequent and generally the result of single values 
outside the normal range (table 3).
table 2 Efficacy outcome measures at week 2, week 16 and week 52† 
Week 2 Week 16 Week 52
Placebo n=109 Apremilast n=110 Placebo n=109 Apremilast n=110
Placebo/Apremilast 
n=91 Apremilast n=80
ACR20, n/m (%) 7/109 (6.4) 18/110 (16.4)* 22/109 (20.2) 42/110 (38.2)‡ 54/90 (60.0) 53/79 (67.1)
ACR50, n/m (%) 2/109 (1.8) 3/110 (2.7) 5/109 (4.6) 20/110 (18.2)‡ 26/91 (28.6) 29/79 (36.7)
ACR70, n/m (%) 0/109 (0.0) 0/110 (0.0) 0/109 (0.0) 7/110 (6.4)* 7/91 (7.7) 17/80 (21.3)
DAS-28 (CRP), mean change −0.31 −0.59* −0.39 −1.07§ −1.46 −1.71
SJC, mean % change −17.5 −27.7 4.2 −46.4§ −71.9 −77.5
TJC, mean % change −16.2 −14.8 2.5 −32.3‡ −61.4 −70.4
GEI (0–6), mean change¶ −0.4 −1.1* −0.4 −1.5‡ −1.4 −1.6
GEI=0¶, n/m (%) 10/51 (19.6) 20/56 (35.7) 17/51 (33.3) 26/56 (46.4) 24/43 (55.8) 30/43 (69.8)
HAQ-DI score (0–3), mean change −0.05 −0.13* −0.06 −0.21* −0.32 −0.40
HAQ-DI MCID ≥0.35, n/m (%) 13/109 (11.9) 24/110 (21.8) 30/109 (27.5) 39/110 (35.5) 38/91 (41.8) 40/80 (50.0)
SF-36v2 PF, mean change NA NA −1.04 2.43‡ 5.11 6.00
SF-36v2 PCS, mean change NA NA −0.31 4.03§ 5.64 6.49
Improvement in morning stiffness 
severity, n/m (%)
23/109 (21.1) 47/110 (42.7)‡ 28/109 (25.7) 51/110 (46.4)‡ 52/91 (57.1) 46/80 (57.5)
Morning stiffness duration 
(minutes), median % change
0.00 0.00* 0.00 −33.33‡ −41.67 −55.00
*P<0.05 versus placebo; based on a Cochran-Mantel-Haenszel test for binary parameters and mixed-effects model for repeated measures for continuous parameters (except 
using stratified Van Elteren test for morning stiffness duration, with last-observation-carried-forward approach for missing data).
†Full analysis set was used for weeks 2 and 16; for response parameters, patients without sufficient data (observed or imputed) for the determination of response status were 
categorised as non-responders. Week 52 analyses were as observed; actual number of patients may vary for each outcome depending on availability of data.
‡P<0.005; §P≤0.0001 versus placebo; based on a Cochran-Mantel-Haenszel test for binary parameters and mixed-effects model for repeated measures for continuous 
parameters (except using stratified Van Elteren test for morning stiffness duration, with last-observation-carried-forward approach for missing data). 
¶Evaluated in patients with enthesitis at baseline (GEI >0).
ACR20, 20% improvement in modified American College of Rheumatology response criteria; DAS-28 (CRP), 28-joint count Disease Activity Score using C reactive protein; GEI, 
Gladman Enthesitis Index; HAQ-DI, Health Assessment Questionnaire-Disability Index; MCID, minimal clinically important differences; NA, not assessed at time point; n/m, 
number of responders/number of patients with sufficient data for evaluation; PCS, physical component summary; PF, Physical Functioning domain; SF-36v2, 36-item Short-Form 
Health Survey version 2.
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Figure 1 (A) ACR20 response, (B) mean per cent change in SJC and (C) mean per cent change in TJC through week 52. All data shown are as 
observed among patients as randomised at baseline and receiving at least one dose of apremilast. ACR20, 20% improvement in modified American 
College of Rheumatology response criteria; n/m, number of responders/number of patients with sufficient data for evaluation; SJC, swollen joint count; 
TJC, tender joint count.
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No patients reported weight decrease as an AE during the 
study; 78.9% of apremilast patients remained within ±5% of 
their baseline weight. At the end of the 52-week period, mean 
weight loss for apremilast patients was −1.20 kg and 15.7% of 
apremilast patients had experienced >5% weight loss.
dIsCussIOn
ACTIVE was the first randomised controlled study to assess the 
onset of response to apremilast monotherapy in biological-naïve 
patients with active PsA. This study demonstrated that at week 
2, many patients had clinical improvements across several PsA 
manifestations, including swollen and tender joints, enthesitis 
(among those with enthesitis at baseline), physical impairment 
and improvement in morning stiffness severity. Likewise, signif-
icant improvements in PsA measures at weeks 16 and 24 were 
observed with apremilast. Treatment response was maintained 
up to week 52 across measures for patients continuing apremilast 
and for placebo patients who switched to apremilast at week 16 
or week 24.
These findings provide new data for apremilast, demon-
strating that a proportion of patients experienced improvements 
in common symptoms of PsA at week 2. Additionally, the use 
of the GEI to assess peripheral entheseal sites in ACTIVE adds 
to our current knowledge of its effect on other entheseal sites, 
as measured by the Maastricht Ankylosing Spondylitis Enthesitis 
Score.
The PALACE studies evaluated apremilast in patients with 
several treatment failures (PALACE 1–3) and as a first-line 
treatment for DMARD-naïve patients (PALACE 4).4–7 Most 
(~70%) of the ACTIVE patient population had exposure to one 
csDMARD. Efficacy in this subpopulation was similar to that 
of the overall population in ACTIVE. These findings further 
support apremilast as a treatment option for patients with PsA 
across the spectrum of treatment experiences.
Figure 2 Proportion of patients achieving a GEI of 0* through week 52. All data shown are as observed among patients as randomised at baseline, 
receiving at least one dose of apremilast and having pre-existing enthesopathy at baseline (eg, GEI score >0, n=102). GEI, Gladman Enthesitis Index; 
n/m, number of responders/number of patients with sufficient data for evaluation.
Figure 3 Mean change from baseline in HAQ-DI score through week 52. All data shown are as observed among patients as randomised at baseline 
and receiving at least one dose of apremilast. HAQ-DI, Health Assessment Questionnaire-Disability Index.
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Apremilast was well tolerated in this biological-naïve PsA 
patient population; additionally, the overall safety profile in 
ACTIVE was found to be consistent with that observed in the 
PALACE studies.4–7 An important study objective was to further 
characterise the gastrointestinal AE of diarrhoea. Overall, fewer 
cases of protocol-defined diarrhoea (two or more watery stools/
day) were observed versus non-defined reported events. This 
criterion is more inclusive than the WHO’s definition of diar-
rhoea of at least three loose or liquid stools/day. Diarrhoea AEs 
typically occurred within the first 4 weeks of treatment, were 
self-limiting, resolving within 15 days and usually did not require 
any major medical treatment.
Apremilast has a unique mechanism of action in modulating 
the expression of both pro-inflammatory and anti-inflammatory 
cytokines16; in ACTIVE, no evidence of increased incidence of 
serious or opportunistic infections and no cases of active tuber-
culosis with 52-week apremilast exposure were observed. Labo-
ratory abnormalities were infrequent and showed no evidence of 
organ toxicity requiring specific monitoring. Safety results were 
consistent with the previous PALACE studies and provide addi-
tional characterisation of AEs of diarrhoea experienced during 
the placebo-controlled phase. The study design for ACTIVE 
allowed for immediate stopping of methotrexate without 
washout, which may be a desired option for some patients in 
routine clinical practice settings. Switching such as this happened 
seamlessly without any significant disease worsening/flares or 
tolerability issues.
limitations
Several limitations should be considered when interpreting 
the study findings and comparing them with other apremilast 
clinical studies. The ACTIVE patient population had base-
line heterogeneity regarding disease duration. Moreover, early 
escape was at the investigator’s discretion, which may be biased 
with apremilast availability on the market. Longer term find-
ings may be biased because patients who did not respond to or 
tolerate treatment may be more likely to discontinue. ACTIVE 
did not evaluate dactylitis, skin and nail outcomes; however, 
apremilast’s impact on such outcomes has been assessed in the 
PALACE6 17 and Efficacy and Safety Trial Evaluating the Effects 
of Apremilast in Psoriasis (ESTEEM) studies.18 19 Additionally, 
this study did not include imaging to evaluate structural damage. 
Morning stiffness findings should be interpreted cautiously, as 
understanding of morning stiffness and PsA disease activity is 
limited.
COnClusIOns
For biological-naïve patients with active PsA, apremilast mono-
therapy resulted in early and sustained improvements across PsA 
manifestations, including swollen and tender joints, enthesitis 
and morning stiffness. No new safety concerns were observed. 
These results support the use of apremilast monotherapy in 
biological-naïve patients with PsA.
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Apremilast 30 mg twice 
daily n=109
Apremilast 30 mg twice daily 
n=206 
Any AE 69 (63.3) 73 (67.0) 144 (69.9) 
Any serious AE‡ 5 (4.6) 3 (2.8) 10 (4.9) 
Any AE leading to study drug withdrawal 5 (4.6) 10 (9.2) 17 (8.3)
Any AE leading to death 0 (0.0) 0 (0.0) 1 (0.5)
AEs with incidence ≥5% in any treatment group
Diarrhoea§ 12 (11.0) 16 (14.7) 33 (16.0)
Nausea 2 (1.8) 9 (8.3) 16 (7.8)
Nasopharyngitis 7 (6.4) 9 (8.3) 16 (7.8)
Headache 4 (3.7) 8 (7.3) 12 (5.8)
Hypertension 7 (6.4) 7 (6.4) 13 (6.3)
Upper respiratory tract infection 11 (10.1) 5 (4.6) 14 (6.8)
Select laboratory assessments, n/m (%)
ALT >3 × ULN, U/L 1/108 (0.9) 1/108 (0.9) 4/205 (2.0)
Creatinine >1.7 × ULN, µmol/L 0/108 (0.0) 0/108 (0.0) 1/205 (0.5)
Haemoglobin value,<10.5 g/dL (male) or <8.5 g/dL (female) 2/108 (1.9) 0/109 (0.0) 2/205 (1.0)
Leucocytes <1.5, 109/L 0/108 (0.0) 0/109 (0.0) 0/205 (0.0)
Neutrophils <1.0, 109/L 1/108 (0.9) 1/109 (0.9) 1/205 (0.5)
Platelets <75, 109/L 1/107 (0.9) 0/109 (0.0) 0/204 (0.0)
*Includes the data through week 16 for placebo patients who escaped, and the data through week 24 for all other patients. 
†Includes all available apremilast-exposure data up to the data cut of 5 November 2015 (including data beyond 52 weeks); patients with multiple reports are only counted once.
‡During the placebo-controlled phase, serious AEs reported by patients on placebo (n=5) were iron deficiency anaemia, angina pectoris, chest pain, cervical vertebral fracture, 
spinal column injury, acute myeloid leukaemia and respiratory papilloma; serious AEs reported by patients on apremilast 30 mg twice daily (n=3) were biliary colic, head injury 
and joint dislocation. New serious AEs of atrial fibrillation, coronary artery disease, alcoholic cardiomyopathy, hypertensive heart disease, cholelithiasis, infective arthritis, bladder 
transitional cell carcinoma, anxiety, ureteric obstruction and arteriosclerosis were reported by seven patients in the cumulative apremilast-exposure period.
§When using protocol-defined characterisation of diarrhoea of two or more watery or liquid stools/day, incidence rates were 8.3% for placebo and 11.0% for apremilast 30 mg 
twice daily during the placebo-controlled phase.
AEs, adverse events; ALT, alanine aminotransferase; n/m, number of patients with at least one occurrence of the abnormality/number of patients with at least one post-baseline 
value; ULN, upper limit of normal.
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